Ono Pharmaceutical Co. Ltd. and Wuxi Apptec Co. Ltd. have jointly developed new ceramide glucosyltransferase (glucosylceramide synthase; GLCT-1) and lysosomal acid glucosylceramidase (GBA; β-glucocerebrosidase; β-glucosidase) dual inhibitors reported to be useful for the treatment of mild cognitive impairment, among others.

Work at Innovstone Therapeutics Ltd. has led to the identification of new dihydrothienopyrimidine derivatives acting as phosphodiesterase PDE4B inhibitors.

A Hitgen Ltd. patent details aromatic-ring compounds acting as E3 ubiquitin-protein ligase (TRIM21) ligands reported to be useful for the treatment of cancer.

Zydus Lifesciences Ltd. has patented new compounds acting as ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2; autotaxin) inhibitors.

Tambo Inc. has described conjugates consisting of payloads covalently linked to trans-cyclooctene through a linker reported to be useful for the treatment of cancer.

CK Regeon Inc. has divulged indirubin derivatives acting as CXXC-type zinc finger protein 5 (CXXC5)/DVL interaction inhibitors reported to be useful for the treatment of skin lesions, wounds, neurodegeneration, metabolic disorders and bone disorders.

Vanderbilt University has identified leucine-rich repeat kinase 2 (LRRK2; dardarin) and LRRK2 (G2019S mutant) inhibitors reported to be useful for the treatment of tauopathies, cancer, Crohn’s disease, type 1 diabetes, leprosy, rheumatoid arthritis, traumatic brain injury and Alzheimer’s disease, among others.

Boehringer Ingelheim Pharma GmbH & Co. KG has synthesized NADPH oxidase 4 (NOX4) inhibitors reported to be useful for the treatment of atherosclerosis, cancer, pulmonary hypertension, inflammatory bowel disease, influenza, retinopathy, sepsis and wet macular degeneration (exudative), among others.

Impact Therapeutics (Shanghai) Inc. has disclosed tricyclic derivatives acting as poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.

Guangdong HEC Pharmaceutical Co. Ltd. has described programmed cell death protein 1 (PD-1)/PD-1 ligand 1 (PD-L1) interaction inhibitors reported to be useful for the treatment of cancer, infections and autoimmune disease.